Scientific SessionEmerging Cellular Therapies – a Role in HL?
Stephen Ansell
Peter Borchmann
09:15–09:35
Clinical experience with Cellular Therapy in cH
Barbara Savoldo
09:35–09:55
Design and manufacturing of CD30 CARs for cHL
Concetta Quintarelli
09:55–10:15
Emerging indications for cellular therapy
Peter Borchmann
10:30 – 12:00
Room: Großer Saal
Scientific SessionLiving beyond Lymphoma
John Radford
Flora van Leeuwen
10:30–10:53
Towards Lung Cancer Screening in Hodgkin Lymphoma Survivors
Kim Linton
10:53–11:16
GHSG data on fertility, fatigue and social reintegration and the ongoing EMBrACe study
Karolin Behringer
11:16–11:21
WS Report: Living beyond Lymphoma
Lena Specht
Flora van Leeuwen
11:21–11:34
Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors
Suzanne Neppelenbroek
11:34–11:47
Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
Joshua Entrop
11:47–12:00
Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study.
Michaela Dinan
12:30 – 13:30
Room: Großer Saal
Satellite Symposium
(by MSD)
Checkpoint Inhibition in Hodgkin Lymphoma – State of the art and future perspectives
Peter Borchmann
12:30–12:50
Firstline therapy of classical Hodgkin Lymphoma – How can immunotherapy improve outcome?
Peter Borchmann
12:50–13:10
The current role of PD-1 inhibition in the treatment of relapsed or refractory classical Hodgkin Lymphoma
Bastian von Tresckow
13:10–13:30
Strategies to enhance checkpoint inhibition
Paul J. Bröckelmann
14:00 – 15:30
Room: Großer Saal
Scientific SessionOlder and Frail Patients
Raul Cordoba Mascuñano
Andrew Evens
14:00–14:23
Managing an Older Lymphoma Patient
Raul Cordoba Mascuñano
14:23–14:46
Treatment Strategies in Older HL Patients
Andrew Evens
14:46–14:51
Workshop Report: Innovation for Older patients
Paul J. Bröckelmann
Alexander Fosså
14:51–15:04
AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients.
Ninja Övergaard
15:04–15:17
The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma
Jenica Upshaw
15:17–15:30
Treatment patterns and outcomes for Hodgkin's Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry
Irene Buvat
16:00 – 17:30
Room: Großer Saal
Satellite Symposium
(by Takeda)
Unraveling Complex Treatment Pathways for Patients with Relapsed / Refractory Hodgkin Lymphoma
Anna Sureda
16:00–16:05
Welcome and introduction
Anna Sureda
16:05–16:25
Navigating Complex Treatment Decisions in R/R HL
Theodoros Vasilakopoulos
16:25–16:40
Challenging Case Study #1
Martin Hutchings
16:40–17:00
Learning from Real-World Evidence to Inform Treatment Decisions in R / R HL
Anna Sureda
17:00–17:15
Challenging Case Study #2
Martin Hutchings
17:15–17:30
Audience Q&A
18:00 – 19:30
Room: Großer Saal
Scientific SessionImmunotherapy
Philippe Armand
Pier Luigi Zinzani
18:00–18:20
New findings and new challenges since last ISHL
Stephen Ansell
18:20–18:33
Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume
Ryan Lynch
18:33–18:45
Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
John Timmerman
19:10–19:18
Vision Corner Stimulus Talk: The future of translational science in HL
Christian Steidl
19:18–19:26
Vision Corner Stimulus Talk: Best use of PD1 blockade in frontline treatment
Graham Collins
19:26–19:34
Vision Corner Stimulus Talk: Leveraging PD1 blockade for cure
Paul J. Bröckelmann
19:34–19:55
Vision Corner: Discussion
Paul J. Bröckelmann
Graham Collins
Christian Steidl
ISHL12 Program at a Glance (PDF)
ISHL12 Final Program
This website uses cookies to ensure you get the best experience on our website.
By using our site you agree to our use of cookies.
Learn more